An open, randomised, parallel group, multicentre study to compare the efficacy and safety of Flutiform pMDI vs Fluticasone pMDI Plus Formoterol DPI in adolescent and adult subjects with mild to moderate-severe persistent, reversible asthma

Trial Profile

An open, randomised, parallel group, multicentre study to compare the efficacy and safety of Flutiform pMDI vs Fluticasone pMDI Plus Formoterol DPI in adolescent and adult subjects with mild to moderate-severe persistent, reversible asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2013

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary) ; Fluticasone propionate; Formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Mundipharma Research
  • Most Recent Events

    • 07 Aug 2012 Additional location (Belgium) added as reported by European Clinical Trials Database.
    • 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
    • 22 Jul 2008 The primary endpoint has been met, according to a SkyePharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top